YM101 demonstrated the ability to bind all 3 isoforms of TGF‐β, and its antitumor activity was better than the combination of anti‐TGF‐β and anti‐PD‐L1 treatments in mouse tumor models [87]. Here, TGFB1 is linked to neoplasm.